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Although previous studies have shown an important role of renal dipeptidyl peptidase-4 (DPP-4) in-
hibition in ameliorating kidney injury in hypertensive rats, the renal distribution of DPP-4 and me-
chanisms of renoprotective action of DPP-4 inhibition remain unclear. In this study, we examined the
effects of the DPP-4 inhibitor saxagliptin on DPP-4 activity in renal cells (using in situ DPP-4 staining) and
on renal gene expression related to inﬂammation and ﬁbrosis in the renal injury in hypertensive Dahl
salt-sensitive (Dahl-S) rats. Male rats fed a high-salt (8% NaCl) diet received vehicle (water) or saxagliptin
(12.7 mg/kg/day) for 4 weeks. Blood pressure (BP), serum glucose and 24-h urinary albumin and sodium
excretions were measured, and renal histopathology was performed. High salt-diet increased BP and
urinary albumin excretion, consequently resulting in glomerular sclerosis and tubulointerstitial ﬁbrosis.
Although saxagliptin did not affect BP and blood glucose levels, it signiﬁcantly ameliorated urinary al-
bumin excretion. In situ staining showed DPP-4 activity in glomerular and tubular cells. Saxagliptin
signiﬁcantly suppressed DPP-4 activity in renal tissue extracts and in glomerular and tubular cells.
Saxagliptin also signiﬁcantly attenuated the increase in inﬂammation and ﬁbrosis-related gene expres-
sions in the kidney. Our results demonstrate that saxagliptin inhibited the development of renal injury
independent of its glucose-lowering effect. Glomerular and tubular DPP-4 inhibition by saxagliptin was
associated with improvements in albuminuria and the suppression of inﬂammation and ﬁbrosis-related
genes. Thus, local glomerular and tubular DPP-4 inhibition by saxagliptin may play an important role in
its renoprotective effects in Dahl-S rats.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dipeptidyl peptidase-4 (DPP-4) inhibitors lower blood glucose
by preventing the degradation of incretin hormone GLP-1 and
gastrointestinal peptide (GIP), and are used widely for the treat-
ment of type 2 diabetes mellitus (Russell-Jones and Gough, 2012).
In addition to an incretin action of DPP-4 inhibitors, DPP-4 in-
hibitors could induce the pleiotropic actions of DPP-4 such as anti-
inﬂammatory, anti-ﬁbrotic and antioxidant effects (Panchapakesan
and Pollock, 2015).
DPP-4, a serine protease, exists in membrane-bound and so-
luble forms; the soluble form in the circulation is thought to arise
from shedding of the membrane-bound formwhich degrades GLP-B.V. This is an open access article u
S. Kunori).1, thus mainly contributing to the control of postprandial blood
glucose levels (Baggio and Drucker, 2007; Panchapakesan and
Pollock, 2015). The membrane-bound form of DPP-4 is expressed
on the surface of many cell types, including kidney tubular cells,
endothelial cells and T cells, and may be responsible for the
pleiotropic actions of DPP-4. In addition, DPP-4 is known to be
responsible for cleavage of various substrates such as brain na-
triuretic peptide (BNP), neuropeptide Y (NPY) and stromal cell-
derived factor-1 (SDF-1), which could affect the additional actions
of DPP-4 inhibition beyond hypoglycemic activity (Muskiet et al.,
2014).
DPP-4 is expressed ubiquitously in various tissues, pre-
dominantly in the kidney (Mentlein, 1999). The membrane bound
form of DPP-4 is expressed on proximal tubular cells, mesangial
cells and podocytes in the kidney (Kettmann et al., 1992). In the
kidney, DPP-4 cleaves several peptides and hormones which reg-
ulate natriuresis, inﬂammation, vascular effects and sympatheticnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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animal studies have demonstrated that DPP-4 inhibitors prevent
renal damage independent of glucose-lowering action (Kanasaki
et al., 2014; Panchapakesan and Pollock, 2015; Tanaka et al., 2014).
Thus, DPP-4 plays an important role in the progression of diabetic
nephropathy.
The SAVOR-TIMI53 trial (16,492 patients with type 2 diabetes)
demonstrated that saxagliptin signiﬁcantly improves the albumin/
creatinine ratio compared with placebo (Scirica et al., 2013). We
recently reported the renoprotective effects of saxagliptin, a potent
DPP-4 inhibitor, in hypertensive Dahl salt-sensitive (Dahl-S) rats,
and indicated the important role of renal tissue DPP-4, but not
circulating, in the progression of hypertension-induced renal in-
jury (Sakai et al., 2015). However, the speciﬁc renal cells targeted
by the action of DPP-4 inhibition and the mechanism of suppres-
sion of renal injury remain unclear. In the present study, we
evaluated DPP-4 activity in renal cells, glomeruli and tubules using
an in situ staining method, and assessed the mechanism of re-
noprotective action of saxagliptin in Dahl-S rats. Here, we report
evidence that saxagliptin suppresses both glomerular and tubular
DPP-4 activities which are associated with a reduction in in-
ﬂammation and ﬁbrotic markers independent of glycemic control
in rat hypertensive renal injury.2. Materials and methods
2.1. Animals
All animals received humane care in compliance with the
“Guiding Principles for the Care and Use of Laboratory Animals”
formulated by the Japanese Pharmacological Society, and all ani-
mal experiments were approved by the Committee for Animal
Experiments of Kyowa Hakko Kirin Co., Ltd. Male Dahl-S rats were
obtained from Japan SLC Inc. (Japan Shizuoka Laboratory Animal
Center, Inc., Japan).
2.2. Experimental procedure
The Dahl rat model is a well-established model of salt-induced
hypertension and kidney injury. In this study, male 6-week-old
Dahl-S rats were fed a high-salt diet (8% NaCl) to induce salt-
sensitive hypertension. Two weeks after the start of the high-salt
diet, Dahl-S rats were divided into two groups and given (1) water
(control, n¼10) and (2) saxagliptin (12.7 mg/kg/day, n¼10) with
drinking water for 4 weeks. Dahl-S rats fed a normal salt diet
(0.19% NaCl) served as the normal group (ND: normal salt diet-fed
Dahl-S rats, n¼5) and were given tap water ad libitum.
Saxagliptin monohydrate (saxagliptin) was obtained from
Bristol Myers Squibb (Pennington, NJ, USA) and was dissolved in
distilled water; the dose of saxagliptin 0.04 mg/ml in drinking
water was almost equal to that of 12.7 mg/kg/day. Urine samples
were collected at 4 weeks after the start of dosing, and urinary
protein, albumin and sodium concentrations were measured.
Systolic blood pressure (SBP) values were measured using the tail-
cuff method at 4 weeks after treatment. After 4 weeks of treat-
ment, rats were anesthetized with isoﬂurane, and then blood and
kidney samples were collected. Blood samples were used for the
measurement of serum glucose, serum creatinine and plasma DPP-
4 activity, and kidney samples were used for the measurement of
DPP-4 activity, in situ DPP-4 staining and histological examination.
2.3. Measurement of plasma and renal DPP-4 activities
DPP-4 activity in plasma and renal extracts was measured as
described previously (Sakai et al., 2015). In brief, the sample wasmixed with 50 mmol/l Gly-Pro-7-AMIDO-4-METHYLCOUMARIN
(Gly-Pro-AMC) in 25 mmol/l of HEPES, 140 mmol/l of NaCl,
80 mmol/l of MgCl2/6H2O, 1 w/v% BSA, pH 7.8 for 20 min at room
temperature. The ﬂuorescence intensity was measured at an ex-
citation wavelength of 460 nm and an emission wavelength of
390 nm. DPP-4 activity was expressed as the AMC amount gen-
erated after 20 min of incubation. The protein concentration of the
supernatant from the renal extract was measured using a BCA
protein assay kit (PIERCE, Rockford, IL, USA).
2.4. In situ staining of DPP-4 activity
Frozen kidney sections (10 mm) were ﬁxed in a mixture of for-
malin, phosphate buffered saline and acetone (1:35:15) and wa-
shed with water. The sections were incubated with a coloring
solution (1.76 mol/l glycyl-prolyl-4-methoxy-β-naphthylamide,
2.52 mol/l Fast Blue B, 3.71 vol% N-N dimethyl formamide,
95.7 mmol/l phosphate buffer) and then washed with water and
dried. The slides were mounted with water and scanned with the
Aperio ScanScopes XT (Aperio Technologies) using a
20objective. Images were analyzed with the Aperio analysis
algorithm (Color deconvolution ver. 9). In situ DPP-4 activity
staining index (H-score) was calculated semiquantitatively as fol-
lows: the staining intensity of DPP-4 positive area was graded into
–, 0; 1þ , 1; 2þ , 2 and 3þ , 3 and the percentage of each positive
area was calculated using Aperio Image Scope software. H-score
was calculated by multiplying the staining intensity (04) by the
percentage of each positive area. One hundred glomeruli and total
area of tubule per section were examined.
2.5. Measurement of renal mRNAs
Total RNA from renal tissue was extracted with RNeasy Fibrous
Tissue Mini Kit (Qiagen). cDNA was synthesized using SuperScript
VILO cDNA Synthesis Kit (Life Technologies). mRNA expression of
the following genes was evaluated by quantitative real-time
polymerase chain reaction (PCR) on a StepOnePlus™ Real-Time
PCR system (Applied Biosystems) using TaqMans Gene Expression
Master Mix (Applied Biosystems): MCP-1: Monocyte Chemoat-
tractant Protein-1 (Rn00580555_m1), TNF-α: Tumor Necrosis
Factor-α (Rn01525859_g1), IL-6: Interleukin-6 (Rn99999011_m1),
PAI-1: Plasminogen Activator Inhibitor-1 (Rn01481341_m1), TGF-
β: Transforming Growth Factor-β (Rn00572010_m1), Col I: type I
Collagen (Rn01463849_g1), Col III: type III Collagen
(Rn01437686_m1), αSMA: α-smooth muscle actin
(Rn01759928_g1). mRNA quantities of target gene were normal-
ized against r18S: 18 S ribosomal RNA (Mm03928990_g1) as a
control gene.
2.6. Histological examination
Kidneys were ﬁxed in 10 vol% neutral buffered formalin solu-
tion and embedded in parafﬁn, and the parafﬁn sections were then
stained with periodic acid-Schiff (PAS) and hematoxylin and eosin
(H&E) for light microscopic observation. Specimens were observed
under a light microscope, and histopathological scoring was per-
formed as described below.
Glomerular injury scores were calculated semiquantitatively as
described previously (Nagase et al., 2006) by examining 100 glo-
meruli per section. Vascular injury score was calculated using a
previously described method (Ishimitsu et al., 1994). Tubulointer-
stitial injury was deﬁned as basophilic tubule, hyaline cast, inter-
stitial inﬂammation and/or tubular dilatation. Each section was
scored on a scale of 0–4, according to the following criteria: 0,
normal; 1, 1% to 25%; 2, 26% to 50%; 3, 51% to 75%; 4, 76% to 100%
of the tubulointerstitial injured area (Shibata et al., 2006).
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All values are expressed as the mean7S.E.M. Statistical ana-
lyses were performed using a statistical analysis software program
(SAS, release 9.2; SAS Institute, Inc., Cary, USA). Differences be-
tween the normal group (ND: normal-salt diet fed Dahl rats) and
the control group (vehicle-treated high-salt diet fed Dahl-S rats),
and the control group and the treatment group were assessed
using Student's t-test, Aspin-Welch test or Wilcoxon rank sum test.
Differences were considered to be statistically signiﬁcant at a P
value of o0.05.3. Results
3.1. Effects on serum glucose, serum creatinine and urinary sodium
excretions
The serum glucose levels of the control group were lower than
those of the normal group (ND). The serum glucose levels in the
saxagliptin group were comparable to those in the normal group.Table 2
Water and food intake, systolic blood pressure, and kidney and heart weights.
ND
(n¼5)
Water intake 974.04747.04
(ml/rat/4 weeks)
Food intake 594.6175.23
(g/rat/4 weeks)
Systolic blood pressure 140.6078.97
(mmHg)
Body weight (B.W.) 386.274.28
(g)
Kidney weight 6.51170.130
(g/kg B.W.)
Heart weight 3.14670.074
(g/kg B.W.)
Values show the mean7S.E.M.
ND: normal salt-diet fed Dahl-S rats.
a P o0.001 compared with the ND group (Student’s t-test).
b P o0.05 compared with the ND group (Student’s t-test).
Table 1
Serum and urinary parameters.
ND
(n¼5)
Serum parameters
Serum glucose 184.40715.25
(mg/dl)
Serum creatinine 0.3170.01
(mg/dl)
Urinary parameters
Urine volume 6.7471.92
(ml/day)
Naþ Excretion 0.6470.12
(mEq/day)
Values show the mean7S.E.M.
ND: normal salt-diet fed Dahl-S rats.
a Po0.001 compared with the ND group (Student's t-test).
b Po0.01 compared with the Control group (Student's t-test).High-salt diets signiﬁcantly increased serum creatinine compared
with the normal group. Saxagliptin signiﬁcantly improved the
increase in serum creatinine in Dahl-S rats (control: 0.4770.02 vs.
saxagliptin: 0.3970.02 mg/dl; Po0.01) (Table 1). High-salt diet
signiﬁcantly increased urinary sodium excretion and urine vo-
lume. Saxagliptin signiﬁcantly increased urinary sodium excre-
tions compared with those in the control group (control:
21.6971.43 vs. saxagliptin: 28.4471.35 mEq/day; Po0.01) but
did not affect urine volume (control: 70.6273.49 vs. saxagliptin:
80.0274.49 ml/day) (Table 1).
3.2. Effects on blood pressure, and relative kidney and heart weights
Systolic blood pressure (SBP) values of the Dahl-S rats fed with
the high-salt diet were higher than those of the rats fed with the
normal diet (control: 232.776.53 vs. normal: 140.678.97 mmHg;
Po0.001). Saxagliptin slightly but not signiﬁcantly decreased
the increase in SBP in the Dahl-S rats (saxagliptin:
218.779.67 mmHg) (Table 2).
Relative weights of kidney and heart were increased by high-
salt diets. Saxagliptin slightly but not signiﬁcantly inhibited theControl Saxagliptin
(n¼10) (n¼10)
3262.18762.29a 3299.97765.86
673.3777.68a 659.6475.83
232.7076.53a 218.7079.67
370.574.53b 377.773.78
9.79670.137a 9.38070.143
4.54370.062a 4.33370.088
Control Saxagliptin
(n¼10) (n¼10)
151.8974.58 180.6076.60b
0.4770.02a 0.3970.02b
70.6273.49a 80.0274.49
21.6971.43a 28.4471.35b
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group (control vs. saxagliptin: kidney weights: 9.79670.137 vs.
9.38070.143 g/kg B.W.; heart weights: 4.54370.062 vs.
4.33370.088 g/kg B.W.) (Table 2).3.3. Effects on urinary protein and albumin excretions
Urinary protein and albumin excretion levels were increased in
the control group compared with those in the normal group (ur-
inary protein: 307.3722.3 vs. 11.071.6 mg/day, urinary albumin:
188.3712.5 vs. 4.370.9 mg/day, respectively, Po0.001). Sax-
agliptin signiﬁcantly inhibited the increase in urinary protein and
albumin excretion after 4 weeks treatment (saxagliptin:
172.8720.1 and 111.1711.7 mg/day, respectively, Po0.001)
(Fig. 1).0
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Fig. 1. Effects on urinary protein (A) and albumin (B) excretion in Dahl-S rats. Data
represent the mean7S.E.M. (n¼5–10). ###: Po0.001 compared with the ND
group (Aspin-Welch test). ***: Po0.001 compared with the Control group (Stu-
dent's t-test). ND: normal salt-diet fed Dahl-S rats.3.4. Renal histological examination
Dahl-S rats fed a high-salt diet exhibited focal-segment or
global glomerulosclerosis with accumulation of amorphous ma-
terials (Fig. 2A). The glomerular injury score in the control group
was signiﬁcantly higher than that in the normal diet group.
Treatment with saxagliptin slightly but not signiﬁcantly sup-
pressed the glomerular injury score (Fig. 2C). Vascular injury
(necrosis, intimal thickening, perivascular inﬂammation, etc.) and
tubulointerstitial injury (basophilic tubule, hyaline cast, etc.) was
also observed in the high-salt fed Dahl-S rats (Fig. 2B). Injury
scores were decreased in the saxagliptin-treated group compared
with the control group (Fig. 2D and E).
3.5. Plasma and renal DPP-4 activity
The levels of plasma and renal DPP-4 activities in the control
group were similar to those in the normal group. Saxagliptin sig-
niﬁcantly inhibited plasma DPP-4 activity by 90% or more (control:
502.4752 pmol, saxagliptin: 49.5711 pmol, Po0.001). Renal
DPP-4 activity was also strongly suppressed by saxagliptin (con-
trol: 76427788 pmol/mg protein, saxagliptin: 17277171 pmol/
mg protein; Po0.001) (Fig. 3).
3.6. In situ DPP-4 activity
The renal tissue DPP-4 activities were stained by colorimetric
assay. Glomeruli and brush border of proximal tubules displayed
DPP-4 activity and were stained in red (Fig. 4A). DPP-4 activity of
blood vessels and distal tubules were not stained, or low in Dahl-S
rats. The intensity of the staining was reduced in the saxagliptin-
treated group compared with the control group (Fig. 4B). H-scores
of staining intensity were decreased signiﬁcantly in the sax-
agliptin-treated group compared with the control group (Fig. 4C
and D).
3.7. Effects on renal gene expressions
The mRNA levels of proinﬂammatory and proﬁbrotic cytokines
such as MCP-1, IL-6, PAI-1, TGF-β, and type I and type III collagen,
were signiﬁcantly up-regulated in the control group compared
with in the normal group. Saxagliptin treatment signiﬁcantly in-
hibited the increase in mRNA levels of TNF-α, IL-6, PAI-1, TGF-β,
type I and type III collagen and α-SMA (Fig. 5).4. Discussion
Our results show for the ﬁrst time that saxagliptin potently
inhibits DPP-4 activity in the kidney, particularly in the glomeruli
and tubules, which is associated with improvement of urinary
albumin excretion in a glucose-independent manner in hy-
pertensive Dahl-S rats. Saxagliptin suppressed the expression of
renal genes related to inﬂammation, such as MCP-1, TNF-α and IL-
6, and ﬁbrosis, such as TGF-β, type I collagen and type III collagen.
Thus, the inhibition of DPP-4 activities in the glomerulus and tu-
bules by saxagliptin may suppress inﬂammation and ﬁbrosis in-
dependently of glycemic control, and thereby inhibit albuminuria
and the progression of nephropathy in the Dahl-S rat model of
hypertension (Fig. 6).
In the present study, we measured renal DPP-4 activity using
an in situ activity staining method and provided the novel ﬁndings
that DPP-4 activities were stained in the glomeruli and brush
border of proximal tubules in Dahl-S rats. Both the staining of
renal DPP-4 activity and inhibition of DPP-4 activity of renal tissue
homogenates were suppressed by saxagliptin (with the same
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Fig. 2. Histopathological examination of the kidney in Dahl-S rats. (A) Representative histological feature of PAS staining: bar¼50 µm. The high-salt diet induced glomerular
lesions (asterisks). (B) Representative histological feature of H&E staining: bar¼50 µm. The high-salt diet induced vascular (arrow) and tubular (arrowheads) lesions. (C–E)
Scores of kidney injuries. Data represent the mean7S.E.M. ##: Po0.01 compared with the ND group,*: Po0.05 compared with the Control group (Wilcoxon rank sum test).
ND: normal salt-diet fed Dahl-S rats.
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knowledge, this is the ﬁrst report which has evaluated the action
of a DPP-4 inhibitor via DPP-4 activity staining. It is well known
that DPP-4 is expressed more prominently in the kidney than in
other organs (Mentlein, 1999). In the kidney, DPP-4 is postulated
to be responsible for regulating endothelial function and natriur-
esis via GLP-1 signaling (Muskiet et al., 2014). In addition, DPP-4
inhibition has also been shown to ameliorate ﬁbrosis and in-
ﬂammation in various animal models (Liu et al., 2012; Higashijimaet al., 2015; Kanasaki et al., 2014; Min et al., 2014; Sakai et al.,
2015). In Dahl-S rats, the renal injury were observed in several
renal cells with no or low expression of DPP-4, such as blood
vessel, interstitial and distal nephron, and thereby the differences
in degree of tissue injuries between the lesions with and without
DPP-4 expression were not detected. Taken together with our
ﬁndings that inhibition of glomerular and tubular DPP-4 activities
by saxagliptin was associated with suppression of glomerulo-
sclerosis and tubulointerstitial ﬁbrosis, our results suggest the
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Fig. 3. Effects on plasma DPP-4 activity (A) and renal DPP-4 activity (B) in Dahl-S
rats. Data represent the mean7S.E.M. (n¼5–10).***: Po0.001 compared with the
Control group (Aspin-Welch test). ND: normal salt-diet fed Dahl-S rats.
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progression of hypertensive nephropathy.
In the current study, renal DPP-4 activity was similar between
the normal and control groups after 6 weeks of a high-salt diet.
The up-regulation of renal DPP-4 has been demonstrated in both
experimental chronic kidney disease models and cases of human
glomerular disease. It has been reported that DPP-4 is expressed in
the kidney in normal animals (Stiller et al., 1991; Kettmann et al.,
1992). In humans, DPP-4 expression is not observed in healthy
individuals whereas increased DPP-4 expression is seen in various
disease states, including cancer, inﬂammation, obesity, and dia-
betes (Röhrborn et al., 2015). Our previous study in Dahl-S rats
showed that renal DPP-4 activity in the control group was elevated
after 1 week of a high-salt diet but that plasma DPP-4 activity
levels were similar between the normal and control groups (Sakai
et al., 2015), suggesting renal DPP-4 may play a critical role in
particular in the early phase of kidney injury. Further studies are
required to determine the role of renal DPP-4 in early phase of
renal injury.We also found evidence that a high-salt diet induced gene
expressions related to inﬂammation, such as MCP-1, IL-6 and PAI-
1, and ﬁbrosis, such as TGF-β, type I collagen and type III collagen.
Saxagliptin signiﬁcantly inhibited these inﬂammatory and ﬁbrotic
parameters and hypertension-induced epithelial-to-mesenchymal
transition (EMT) including α-SMA expression. Inﬂammation and
ﬁbrosis, as well as hypertension, are common factors involved in
the development of renal injury in diabetes and other diseases,
and DPP-4 inhibition has previously been shown to ameliorate
ﬁbrosis and inﬂammation in various animal models (Liu et al.,
2012; Kanasaki et al., 2014; Min et al., 2014). Panchapakesan and
others have also shown the potential mechanisms of re-
noprotective action of DPP-4 inhibitors independent of glucose
lowering (Panchapakesan and Pollock, 2015; Gangadharan Komala
et al., 2015). In a mouse model of type I diabetes, saxagliptin im-
proved TGF-β-mediated renal ﬁbrosis and NF-κB-mediated in-
ﬂammation (Gangadharan Komala et al., 2015). Taken together
with these reports, our mechanistic data suggest that saxagliptin
inhibits glomerular and tubulointerstitial ﬁbrosis through sup-
pression of inﬂammation, TGF-β-mediated collagen deposition
and phenotypic modulation, independent of glycemic action.
In this study, saxagliptin slightly decreased blood pressure but
not statistically signiﬁcant effects. Recent reports have shown that
incretin drugs have antihypertensive and natriuretic effects in
experimental models. GLP-1 also induces antihypertensive effects
by its diuretic and natriuretic effects (Yu et al., 2003). Suﬁun et al.
(2015) have shown that GLP-1 by DPP-4 inhibition also enhances
diuresis and natriuresis, thereby decreasing blood pressure in
Dahl-S rat. These reports suggest that the diuretic and natriuretic
action of GLP-1 cause antihypertensive effects in Dahl-S rats. In the
present study, treatment of saxagliptin signiﬁcantly increased ur-
inary sodium excretion but did not affect urine volume. The data of
no effect of saxagliptin on urine volume might support the results
that saxagliptin did not affect blood pressure in Dahl-S rats. Thus,
renal DPP-4 inhibition by saxagliptin prevented increase in albu-
minuria independently of blood pressure.
Our results show that saxagliptin inhibits glomerular and
tubular DPP-4 activities in Dahl-S rats. Saxagliptin is tightly bound
to DPP-4 covalently, and its effect seems to exhibit a slow-binding
behavior with a t1/2 during dissociation of 50 min (Wang et al.,
2012). Saxagliptin is ﬁltered at the glomerulus and excreted in the
urine (Su et al., 2012). Therefore, as membrane-bound DPP-4 is
expressed on the tubular brush border membrane (Kettmann
et al., 1992), ﬁltered saxagliptin presumably acts on DPP-4 on the
brush border membrane. It has recently been shown that tubu-
lointerstitial ﬁbrosis is improved by saxagliptin treatment in
streptozotocin (STZ)-induced diabetic eNOS knockout (eNOS KO)
mice (Gangadharan Komala et al., 2015). In a mouse model of
kidney ﬁbrosis, DPP-4 inhibition reduced inﬂammation and ﬁ-
brosis (Min et al., 2014). Thus, tubular DPP-4 inhibition by sax-
agliptin may contribute to the amelioration of tubulointerstitial
ﬁbrosis via suppression of TGF-β and inﬂammation signaling.
Saxagliptin strongly inhibited glomerular DPP-4 staining as well as
signiﬁcantly reducing urinary albumin excretion in Dahl-S rats. In
another study using eNOS KO mice, however, saxagliptin had no
inhibitory action on albuminuria and glomerular sclerosis (Gang-
adharan Komala et al., 2015). A recent study has shown that sax-
agliptin reduces blood pressure and inﬂammation while enhan-
cing NO production in glomerular endothelium in hypertensive
rats (Mason et al., 2012). Saxagliptin reverses vascular remodeling
and ameliorates NO availability in db/db mice (Solini et al., 2015).
These reports suggest that saxagliptin is likely to not suppress
albuminuria and glomerulosclerosis in diabetic eNOS KO mice that
endothelial NO production by saxagliptin is not expected (Gang-
adharan Komala et al., 2015). Consequently, in the glomerulus, NO
production from the endothelium by saxagliptin is probably
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Fig. 4. In situ DPP-4 activity staining of the kidney in Dahl-S rats. (A) Representative high-magniﬁcation images of DPP-4 staining in the ND group: bar¼50 µm. Positive
reaction is observed in glomerulus and brush border of proximal tubules. (B) Representative low-magniﬁcation images of DPP-4 staining: bar¼100 µm. The intensity of the
staining is reduced in saxagliptin group compared with that in the ND and the Control group. (C and D) H-scores of DPP-4 activity staining. Data represent the mean7S.E.M.
###: Po0.001 compared with the ND group; ***: Po0.001 compared with the Control group (Wilcoxon rank sum test). ND: normal salt-diet fed Dahl-S rats.
M. Uchii et al. / European Journal of Pharmacology 783 (2016) 56–6362attributable to the prevention of albuminuria and glomerular
sclerosis. In Dahl hypertensive rats, even though circulating DPP-4
activity levels were comparable, saxagliptin inhibited renal DPP-4
activity more potently than other DPP4inhibitor sitagliptin, and
the inhibitory action of saxagliptin was associated with improve-
ments in albuminuria (Sakai et al., 2015). Covalent binding of
saxagliptin and DPP-4 may contribute to potent membrane-bound
DPP-4 inhibition in glomerular and tubular cells. On the basis of
these ﬁndings, we postulate that inhibition of both glomerular andtubular DPP-4 is important for the prevention of hypertensive
renal injury.
In conclusion, the highly potent and long-binding DPP-4 inhibitor
saxagliptin inhibited the development of renal injury independent of
its glucose-lowering effect. Glomerular and tubular DPP-4 inhibition
by saxagliptinwas associated with improvements in albuminuria and
the suppression of renal inﬂammation and ﬁbrosis. Thus, local glo-
merular and tubular DPP-4 inhibition by saxagliptin may play an
important role in its renoprotective effects in Dahl-S rats.
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Fig. 5. Effects on gene expression of inﬂammation and ﬁbrotic markers in Dahl-S
rats. Data represent the mean7S.E.M. (n¼5–10). #: Po0.05, ##: Po0.01 and
###: Po0.001 compared with the ND group (Aspin-Welch test), ††: Po0.01
compared with the ND group (Student's t-test). *: Po0.05 compared with the
Control group (Aspin-Welch test), $: Po0.05 and $$: Po0.01 compared with the
Control group (Student's t-test). ND: normal salt-diet fed Dahl-S rats; MCP-1:
Monocyte Chemoattractant Protein-1; TNF-α: Tumor Necrosis Factor-α; IL-6: In-
terleukin-6; PAI-1: Plasminogen Activator Inhibitor-1; TGF-β: Transforming Growth
Factor-β1; Col I: type I Collagen; Col III: type III Collagen; α-SMA: α-smooth muscle
actin; r18S: 18 S ribosomal RNA.
Fig. 6. Potential GLP-1 independent/dependent mechanisms of DPP-4 inhibition
with saxagliptin in the development of renal injury. MCP-1: Monocyte Chemoat-
tractant Protein-1; TNF-α: Tumor Necrosis Factor-α; IL-6: Interleukin-6; PAI-1:
Plasminogen Activator Inhibitor-1; TGF-β: Transforming Growth Factor-β1; Col I:
type I Collagen; Col III: type III Collagen; α-SMA: α-smooth muscle actin; EMT:
Epithelial-Mesenchymal Transition.
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